Fluoxetine
Drug20-40 mg / day orally
NCT Number: NCT00714779
In this study we compare two treatments for major depression - fluoxetine and brief psychodynamic psychotherapy. In addition to more traditional outcome measures, we also measure the densities of 5HT-1A and D-2 receptors before and after the treatment. The main hypothesis is that brief psychotherapy is as effective as fluoxetine.
Looking for future studies?
Notify Me20 year–60 year
All sexes
Interventional
Not applicable
This study is a randomized comparison of two treatments for major depression - fluoxetine and brief psychodynamic psychotherapy. The patients are recruited from occupational health services and suffer from mild to moderate major depressive disorder. The treatments last for 16 weeks. The main outcome measures include HAM-D, BDI, SOFAS, Rand-36. In addition to more traditional outcome measures, we also measure the densities of 5HT-1A and D-2 receptors before and after the treatment using Positron Emission Tomography (PET) . The main hypothesis is that brief psychotherapy is as effective as fluoxetine, but differences between the treatments are seen in PET scanning.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
20-40 mg / day orally
1 session / week for 16 weeks
Time frame: 0, 16 weeks, one year
Looking for future studies?
Notify MeUniversity of Turku
Other
Fluoxetine vs. Brief Psychotherapy in the Treatment of Major Depression - a Randomized Comparative Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05376150
Behavior, Behavioral Symptoms
Anaheim, California, United States
View Trial DetailsNCT05544071
Depressive Disorder, Depressive Disorder, Major
Xi'an, Shaanxi, China
View Trial DetailsNCT06236880
Depressive Disorder, Depressive Disorder, Major
Manchester, United Kingdom
View Trial DetailsNCT02607514
Behavior, Behavioral Symptoms
Boston, Massachusetts, United States
View Trial Details